Filtered By:
Countries: Japan Health
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 2168 results found since Jan 2013.
Risk and population attributable fraction of stroke subtypes in Japan
CONCLUSION: Although there are differences according to the subtypes, hypertension could be regarded as the most crucial target for preventing strokes in Japan.PMID:37460296 | DOI:10.2188/jea.JE20220364
Source: Journal of Epidemiology - July 17, 2023 Category: Epidemiology Authors: Hiroshi Yatsuya Kazumasa Yamagishi Yuanying Li Isao Saito Yoshihiro Kokubo Isao Muraki Manami Inoue Shoichiro Tsugane Hiroyasu Iso Norie Sawada Source Type: research
Time-to-treatment with endovascular thrombectomy in patients with large core ischemic stroke: the 'late window paradox
The results of the recently published randomized clinical trials of endovascular thrombectomy (EVT) for large vessel occlusion (LVO) in acute ischemic stroke (AIS) patients with a large ischemic core: ANGEL-ASPECT,1 SELECT-2,2 and the RESCUE-Japan LIMIT trials,3 are promising and are expected to lead to more AIS-LVO patients undergoing EVT. Prior studies have demonstrated that shorter time-to-treatment has been found to be directly associated with better functional outcomes in AIS-LVO patients undergoing EVT.4 In this short commentary, we have pooled the available data from the abovementioned trials to conduct a subgroup a...
Source: Journal of NeuroInterventional Surgery - July 14, 2023 Category: Neurosurgery Authors: Al-Mufti, F., Elfil, M., Ghaith, H. S., Ghozy, S., Elmashad, A., Jadhav, A. P., Gandhi, C. D., Mayer, S. Tags: Commentary Source Type: research
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Probabilistic graphical modelling using Bayesian networks for predicting clinical outcome after posterior decompression in patients with degenerative cervical myelopathy
CONCLUSIONS: The causal predictors of surgical outcome for DCM were sex, dementia and PreJOA score. Therefore, PGM may be a useful personalized medicine tool for predicting the outcome of patients with DCM.PMID:37435966 | DOI:10.1080/07853890.2023.2232999
Source: Annals of Medicine - July 12, 2023 Category: Internal Medicine Authors: Dong Ah Shin Sun-Ho Lee Sohee Oh Changwon Yoo Hee-Jin Yang Ikchan Jeon Sung Bae Park Source Type: research
Improved language function for post-stroke aphasia in the long term following repeated repetitive transcranial magnetic stimulation and intensive speech-language-hearing therapy: a case report
ConclusionsThe findings of the study indicate that the repeated use of repetitive transcranial magnetic stimulation and intensive speech-language-hearing therapy may be effective in improving and preserving language function and increasing cerebral blood flow for aphasia following stroke.
Source: Journal of Medical Case Reports - July 8, 2023 Category: General Medicine Source Type: research
Protective effects of Japanese sake yeast on depressive-like behaviors, oxidative stress and inflammatory parameters in a rat model of global cerebral ischemia/reperfusion
This study evaluates the effects of sake yeast on depressive-like behaviors, oxidative stress and inflammatory parameters in a rat model of global cerebral ischemia/reperfusion. Rats were divided into four groups, including 1) control: without bilateral common carotid artery occlusion (BCCAO) and sake supplement, 2) Ischemia group: rats induced with BCCAO and lack of therapeutic supplement, and 3 and 4) Ischemia + sake groups: rats induced with BCCAO and treated with 25 and 50 mg/kg sake yeast, respectively. Depressive-like behaviors antioxidant enzymes activities were assessed. The induction of stroke increased oxidant st...
Source: Biochemical and Biophysical Research communications - July 7, 2023 Category: Biochemistry Authors: Maryam Vaghari Akbar Hajizadeh Moghaddam Mojtaba Ranjbar Nasrollah Moradikor Source Type: research
Qure.ai wins Japan QuickFire challenge
AI radiology software company Qure.ai has won the Japan Smart Healthy Agin...Read more on AuntMinnie.comRelated Reading:
World record achieved for x-ray at highest altitude
Qure.ai joins forces with Nuance
Medtronic and Qure.ai partner to advance AI stroke management
AI helps improve TB screening in Nigeria
Qure.ai, Therapixel enter into distribution partnership
Source: AuntMinnie.com Headlines - July 5, 2023 Category: Radiology Source Type: news
Validity of functional assessment for control of trunk in patients with subacute stroke: a multicenter, cross-sectional study
Conclusion] For inpatients with stroke, FACT offered feasibility, criterion validity, and construct validity.PMID:37405187 | PMC:PMC10315203 | DOI:10.1589/jpts.35.520
Source: Health Physics - July 5, 2023 Category: Physics Authors: Yutaka Okuda Go Owari Shinichi Harada Masayoshi Uchiyama Masaki Fukunaga Masatake Ikegami Shinya Oteki Daiki Yamada Miho Yamada Shigeru Usuda Source Type: research
